Cargando…

Case Report: Favorable Response to the Tyrosine Kinase Inhibitor Apatinib in Recurrent Merkel Cell Carcinoma

BACKGROUND: As angiogenesis is an essential step in tumor growth and metastasis, the tyrosine kinase inhibitor (TKI) apatinib has become a revolutionary anticancer therapy across various malignancies. However, its efficiency and safety in Merkel cell carcinoma (MCC) are uncertain. CASE PRESENTATION:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Yiyi, Song, Xin, Jia, Renbing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966513/ https://www.ncbi.nlm.nih.gov/pubmed/33747940 http://dx.doi.org/10.3389/fonc.2021.625360

Ejemplares similares

Case Report: Durable Response to Very Low Dose Tyrosine Kinase Inhibitors in Advanced Hepatocellular Carcinoma
por: Tang, Tin-Yun, et al.
Publicado: (2021)

Improving Outcomes of Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma: New Data and Ongoing Trials
por: Mou, Lisha, et al.
Publicado: (2021)

Treatment Response, Survival Benefit and Safety Profile of PD-1 Inhibitor Plus Apatinib Versus Apatinib Monotherapy in Advanced Colorectal Cancer Patients
por: Pan, Dengdeng, et al.
Publicado: (2022)

Third Generation Tyrosine Kinase Inhibitors and Their Development in Advanced Renal Cell Carcinoma
por: Bukowski, Ronald M.
Publicado: (2012)

Apatinib Plus Temozolomide: An Effective Salvage Treatment for Recurrent Glioblastoma
por: Ge, Jingjing, et al.
Publicado: (2021)

Merkel Cell Carcinoma: An Update and Immunotherapy
por: Uchi, Hiroshi
Publicado: (2018)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
por: Yang, Fei, et al.
Publicado: (2022)

Recurrent Gallbladder Carcinoma With pMMR/MSS Achieved a Complete Response Following Camrelizumab Combined With Apatinib: A Case Report
por: Zhong, Liting, et al.
Publicado: (2022)

Tyrosine kinase inhibitors, ionic currents, and cardiac arrhythmia
por: Hu, Chi-Hao, et al.
Publicado: (2023)

Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?
por: Tanda, Enrica Teresa, et al.
Publicado: (2021)

Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediate‐Stage Hepatocellular Carcinoma, What Else Can We Do?
por: Deng, Jun, et al.
Publicado: (2022)

The impact of merkel cell polyomavirus positivity on prognosis of merkel cell carcinoma: A systematic review and meta-analysis
por: Yang, Aimin, et al.
Publicado: (2022)

Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients
por: Tarabadkar, Erica S., et al.
Publicado: (2018)

Evaluation of tyrosine kinase inhibitors combined with antiprogrammed cell death protein 1 antibody in tyrosine kinase inhibitor-responsive patients with microsatellite stable/proficient mismatch repair metastatic colorectal adenocarcinoma: protocol for open-label, single-arm trial
por: Dong, Qian, et al.
Publicado: (2022)

Histogenesis of Merkel Cell Carcinoma: A Comprehensive Review
por: Kervarrec, Thibault, et al.
Publicado: (2019)

Kidney metastasis in a case of Merkel cell carcinoma
por: Motaouakil, Abdessamade, et al.
Publicado: (2021)

Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report
por: Chai, Peiwei, et al.
Publicado: (2020)

Apatinib Treatment in Metastatic Gastrointestinal Stromal Tumor
por: Cai, Zhaolun, et al.
Publicado: (2019)

Epidermal Growth Factor Receptor Mutation Status and Response to Tyrosine Kinase Inhibitors in Advanced Chinese Female Lung Squamous Cell Carcinoma: A Retrospective Study
por: Chang, Qing, et al.
Publicado: (2021)

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety
por: García-Gutiérrez, Valentín, et al.
Publicado: (2019)

Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: A tertiary medical center experience
por: Luo, Laihui, et al.
Publicado: (2022)

The Role of Histone Post-Translational Modifications in Merkel Cell Carcinoma
por: Mazziotta, Chiara, et al.
Publicado: (2022)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kwok, Christopher, et al.
Publicado: (2023)

Response to Anti-PD-1 Therapy in Metastatic Merkel Cell Carcinoma Metastatic to the Heart and Pancreas
por: Mantripragada, Kalyan, et al.
Publicado: (2015)

Merkel Cell Polyoma Viral Load and Intratumoral CD8+ Lymphocyte Infiltration Predict Overall Survival in Patients With Merkel Cell Carcinoma
por: von der Grün, Jens, et al.
Publicado: (2019)

Stimulation of Let-7 Maturation by Metformin Improved the Response to Tyrosine Kinase Inhibitor Therapy in an m6A Dependent Manner
por: Li, Kai, et al.
Publicado: (2022)

Case Report: Low-Dose Apatinib in the Treatment of Intrahepatic Biliary Cystadenoma With Recurrence and Malignant Transformation
por: Yang, Yongguang, et al.
Publicado: (2021)

Impact of Tyrosine Kinase Inhibitors (TKIs) Combined With Radiation Therapy for the Management of Brain Metastases From Renal Cell Carcinoma
por: Khan, Muhammad, et al.
Publicado: (2020)

Survival After Combining Stereotactic Body Radiation Therapy and Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma
por: Liu, Yang, et al.
Publicado: (2021)

BCR-ABL1 Doubling-Times and Halving-Times May Predict CML Response to Tyrosine Kinase Inhibitors
por: Pennisi, Maria Stella, et al.
Publicado: (2019)

Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors Using Dried Blood Microsamples
por: Verougstraete, Nick, et al.
Publicado: (2022)

Adverse events and dose modifications of tyrosine kinase inhibitors in chronic myelogenous leukemia
por: Yoshifuji, Kota, et al.
Publicado: (2022)

Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models
por: Kaehler, Meike, et al.
Publicado: (2023)

A Therapeutic and Diagnostic Multidisciplinary Pathway for Merkel Cell Carcinoma Patients
por: Rastrelli, Marco, et al.
Publicado: (2020)

Efficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review
por: Tian, Zhichao, et al.
Publicado: (2021)

Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kan, Xuefeng, et al.
Publicado: (2020)

Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib
por: Wu, Wen-Chi, et al.
Publicado: (2023)

Clinical Outcomes and Prognosis Factors of Nivolumab Plus Chemotherapy or Multitarget Tyrosine Kinase Inhibitor in Multi-Line Therapy for Recurrent Hepatitis B Virus-Related Hepatocellular Carcinoma: A Retrospective Analysis
por: Chen, Chao, et al.
Publicado: (2020)

Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study
por: Li, Ling, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_80ummgr1t30mb56b0tcoh3crsm